Horizon One Clinical Trial
If you or a loved one has multiple myeloma that has come back or stopped responding to treatment, you may be able to take part in a research study testing new and innovative therapies.
What is Horizon One?
Horizon One is a unique clinical trial (known as an adaptive platform trial) sponsored by the Multiple Myeloma Research Foundation.
As an adaptive platform trial, Horizon One is designed to test and evaluate multiple treatment approaches at the same time. When new therapies become available, they can be added to the study as new groups (also called “arms”). Patients will be enrolled into all open arms and the trial can continue to grow and evolve as research advances. Each treatment arm is studied separately, and new arms may open or close over time depending on how well the treatments are performing.
This flexible design helps researchers:
- Study promising treatments more quickly
- Learn what works best for patients sooner
- Continuously improve options for people with multiple myeloma
What treatment is Horizon One testing?
The current study arm is testing whether the drug Tecvayli (Teclistamab) can be given less frequently or potentially stopped entirely in certain patients, with the goal of maximizing how well it works while minimizing side effects.
The study is evaluating:
- The best dose and schedule for treatment
- How well the treatment works for patients whose disease has relapsed or is refractory
Researchers will monitor:
- How well the treatment controls myeloma
- Side effects and safety
- Patients’ overall health and quality of life
What is Tecvayli?
Tecvayli is a type of treatment called a bispecific antibody, like Lynozyfic (linvoseltamab), Elrexfio (Elranatamab), or Talvey (Talquetamab). It works by helping your immune system recognize and attack multiple myeloma cells.
This medicine is already approved for some patients with relapsed multiple myeloma, and this study is exploring how it may work earlier or in different does.
Who may be able to join?
You may be eligible if you:
- Are 18 years or older
- Have been diagnosed with multiple myeloma
- Have disease that has returned or stopped responding to treatment
- Have previously received certain myeloma therapies
A study doctor will review your medical history to determine whether the trial may be appropriate for you.
Is there financial support available?
Yes – the MMRF has partnered with Family Reach to offer grants to help cover non-medical expenses, including mortgage/rent payments, utilities, groceries, and transportation. If you have questions, please contact [email protected] or call them at (857) 233-2764.
Questions to Ask Your Doctor
If you are considering this trial, you may want to ask your doctor:
- Is this study appropriate for my type of myeloma?
- What are the possible risks and benefits?
- How might participation affect my current treatment plan?
Am I eligible?
The MMRF Patient Navigation Center (PNC) can help answer any additional questions you have about Horizon One, and can even pre-screen you to see if you are eligible for Horizon or other clinical trials. Contact the PNC today to learn more.